1. Home
  2. TSAT vs LCTX Comparison

TSAT vs LCTX Comparison

Compare TSAT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telesat Corporation

TSAT

Telesat Corporation

HOLD

Current Price

$50.79

Market Cap

390.1M

Sector

Industrials

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.63

Market Cap

391.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSAT
LCTX
Founded
1969
1990
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.1M
391.1M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
TSAT
LCTX
Price
$50.79
$1.63
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$37.00
$5.33
AVG Volume (30 Days)
172.2K
1.0M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,556,000.00
Revenue This Year
N/A
$109.40
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.24
52 Week Low
$14.81
$0.40
52 Week High
$47.90
$2.09

Technical Indicators

Market Signals
Indicator
TSAT
LCTX
Relative Strength Index (RSI) 71.55 54.06
Support Level $22.04 $1.56
Resistance Level N/A $1.82
Average True Range (ATR) 3.55 0.08
MACD 0.76 0.02
Stochastic Oscillator 96.21 74.47

Price Performance

Historical Comparison
TSAT
LCTX

About TSAT Telesat Corporation

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: